A Safety Study of Mirikizumab (LY3074828)

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Psoriasis
Interventions
BIOLOGICAL

Mirikizumab- IV

Administered IV

BIOLOGICAL

Mirikizumab - SC

Administered SC

BIOLOGICAL

Placebo - IV

Administered IV

Trial Locations (2)

N2J 1C4

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waterloo

H2K4L5

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT01947933 - A Safety Study of Mirikizumab (LY3074828) | Biotech Hunter | Biotech Hunter